Why Is McKesson Stock Trading Lower Today? - McKesson (NYSE:

McKesson beats expectations with Q3 2024 sales of $80.9 billion, up 15%. U.S. Pharmaceutical Segment thrives, adjusted EPS at $7.74, exceeding consensus.

Related Keywords

Allison Jacobsen , Mckesson Corporation , Eric Coldwell , Citigroup , Prescription Technology Solutions , Mckesson , Prescription Technology Solutions Segment , Rite Aid , Prescription Technology Solutions Rx , Technology Solutions Segment , Bankrupt Rite Aid , Prescription Technology , Technology Solutions ,